IMU (ASX) Ann: Quarterly Activities/Appendix 4C Cash Flow Report

Originally posted by Watmighthavben: ↑

My take on the quarterly activities report is that Imugene appear to be devoting much time to recruiting sites for their clinical trials when perhaps the focus needs to change toward educating oncologists and in turn recruiting patients to them. Historically speaking there appears to be a very slow take up in many of their clinical trials with participants always on the minimal side, despite the large number of sites in play. The FDA allows Imugene to recruit between 3 - 6 patients per cohort in some of their trials, only to find its always closer to 3 enrolled. We only now hear as at May 2023 of one patient enrolled in the much lauded OASIS Trial for solid tumours when close to 90 percent of all cancer patients suffer with solid tumour diagnosis. With the right information surely oncologists in the US let alone Australia would be jumping all over this for their patients. Likewise PD1 Vaxx, the Imprinter Trial and the supposed supply agreement with Roche. What there aren't enough lung cancer patients out there worthy of Professor Kauamaya's already successful B cell vaccine, and a subsequent update in this Quarterly Activities Report?

Imugene promises much at the commencement of these trials, but attaining an FDA IND and dosing the first patients is but a small part of the job done. Their Her-Vaxx Keytruda Combination Trial being but one example. Big Pharma is often seen spending large sums recruiting hundreds if not thousands of patients to their clinical trials (i.e, competitors Enhertu and Jemperli). I realise for whatever reason Imugene does not wish to hop on board with them in the early stage of drug development, but from where I sit with low participation numbers its beginning to hurt them. A slow boat to China may have been ok a decade ago, but now the world of cancer research is moving at a rapid clip. With quantum computing and AI on the uptick vaccines are being tried and tested in years, not decades. Within a few years these timelines may be reduced to months. I would like to see Imugene rapidly expand their existing clinical trials to amass much more meaningful data through larger sample sizes across the broad spectrum of cancer indications. After close to two years in the clinic the company's flagship candidate Vaxinia now has only 20 patients on ongoing therapy. Whilst that may be suitable for some, I see the sample size as being far too small given the drugs exciting potential pre clinically. Particularly now the CF33 TNBC Trial appears dead in the water.

A rethink of trial expansion, commercial direction and supply/partnership agreements is required from the top down if Imugene is to deliver on investor expectations. The shareholders I'm confident would support the necessary company expansion to create more of the aforementioned data, be it via the NASDAQ, partnership or out licensing route. But clearly decisions need to be made sooner rather than later. PD1 Vaxx and in particular their extensive oncolytic viral arm and ancillary products need a real "pick me up" when one assesses these activities from an objective viewpoint, as opposed to the subjective view of a rusted on shareholder.

DYOR Seek investment advice as and when required Opinions only

Expand

"Educating oncologists" about what exactly? People are talking as if imugene have had a trial with significant results.

No.	Vol.	Price($)
8	1882949	5.8¢

No.

Vol.

Price($)

1882949

5.8¢

Price($)	Vol.	No.
5.9¢	399643	3

Price($)

Vol.

No.

5.9¢

399643

No.	Vol.	Price($)
7	1874329	0.058
9	1728227	0.057
23	4466894	0.056
27	3648665	0.055
8	305000	0.054

No.

Vol.

Price($)

1874329

0.058

1728227

0.057

4466894

0.056

3648665

0.055

305000

0.054

Price($)	Vol.	No.
0.059	1360	1
0.060	2622845	17
0.061	773907	4
0.062	2227969	6
0.063	243179	3

Price($)

Vol.

No.

0.059

1360

0.060

2622845

0.061

773907

0.062

2227969

0.063

243179

(20min delay)
Last 5.9¢		Change 0.000(0.00%)		Mkt cap ! $431.8M

Open	High	Low	Value	Volume
5.9¢	5.9¢	5.6¢	$1.037M	17.94M

"Educating oncologists" about what exactly? People are talking...

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

Strike Energy secures $153 million for Perth Basin gas projects

Emyria's Empax Centre chosen for mental health clinical trial

Belararox delineates another porphyry in Argentina at Tambo South

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

Frontier Energy achieves key milestone for Waroona energy project

Cultural heritage agreement puts Walford Creek exploration back on the map

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

"Educating oncologists" about what exactly? People are talking...

Top Stories

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

Strike Energy secures $153 million for Perth Basin gas projects

Emyria's Empax Centre chosen for mental health clinical trial

Belararox delineates another porphyry in Argentina at Tambo South

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

Frontier Energy achieves key milestone for Waroona energy project

Cultural heritage agreement puts Walford Creek exploration back on the map

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News